This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): budesonide/formoterol, Symbicort Turbuhaler (Japan)
Description: Symbicort is in development to treat asthma and COPD. It provides both the anti-inflammatory corticosteroid budesonide (Pulmicort) and the rapid- and long-lasting bronchodilator formoterol (Foradil) in a single inhaler. Formulations include the pMDI (metered-dose inhaler) and Turbohaler (powdered formulation), though the latter is not being developed in the US.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Symbicort was originally developed by AstraZeneca.
In August 2009, AstraZeneca and Astellas Pharma announced that the companies concluded an agreement for the co-promotion of Symbicort Turbuhaler for the treatment of bronchial asthma in Japan.
Pursuant to the Agreement, while AstraZeneca will manufacture and develop, and Astellas will distribute and sell the product, AstraZeneca and Astellas will jointly carry out promotion of the product. Based upon the Agreement, Astellas will make an upfront payment of 3.0 billion yen to AstraZeneca in addition to milestone payments of up to 5.5 billion yen depending on the achievement of certain sales and approval of an additional indication by the Japanese authority.
Partners: Astellas Pharma, Inc.
Additional information available to subscribers only: